From Stress to Sick(le) and Back Again-Oxidative/Antioxidant Mechanisms, Genetic Modulation, and Cerebrovascular Disease in Children with Sickle Cell Anemia

Overview

Journal Antioxidants (Basel)

Date 2023 Nov 25

PMID 38001830

Authors

Marisa Silva

Paula Faustino

Affiliations

Soon will be listed here.

Abstract

Sickle cell anemia (SCA) is a genetic disease caused by the homozygosity of the :c.20A>T mutation, which results in the production of hemoglobin S (HbS). In hypoxic conditions, HbS suffers autoxidation and polymerizes inside red blood cells, altering their morphology into a sickle shape, with increased rigidity and fragility. This triggers complex pathophysiological mechanisms, including inflammation, cell adhesion, oxidative stress, and vaso-occlusion, along with metabolic alterations and endocrine complications. SCA is phenotypically heterogeneous due to the modulation of both environmental and genetic factors. Pediatric cerebrovascular disease (CVD), namely ischemic stroke and silent cerebral infarctions, is one of the most impactful manifestations. In this review, we highlight the role of oxidative stress in the pathophysiology of pediatric CVD. Since oxidative stress is an interdependent mechanism in vasculopathy, occurring alongside (or as result of) endothelial dysfunction, cell adhesion, inflammation, chronic hemolysis, ischemia-reperfusion injury, and vaso-occlusion, a brief overview of the main mechanisms involved is included. Moreover, the genetic modulation of CVD in SCA is discussed. The knowledge of the intricate network of altered mechanisms in SCA, and how it is affected by different genetic factors, is fundamental for the identification of potential therapeutic targets, drug development, and patient-specific treatment alternatives.

References

Belcher J, Chen C, Nguyen J, Milbauer L, Abdulla F, Alayash A . Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2013; 123(3):377-90. PMC: 3894494. DOI: 10.1182/blood-2013-04-495887. View

Ware R, Davis B, Schultz W, Brown R, Aygun B, Sarnaik S . Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2015; 387(10019):661-670. PMC: 5724392. DOI: 10.1016/S0140-6736(15)01041-7. View

Gladwin M, Sachdev V, Jison M, Shizukuda Y, Plehn J, Minter K . Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004; 350(9):886-95. DOI: 10.1056/NEJMoa035477. View

Powars D, Chan L, Hiti A, Ramicone E, Johnson C . Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore). 2005; 84(6):363-376. DOI: 10.1097/01.md.0000189089.45003.52. View

Kassim A, Pruthi S, Day M, Rodeghier M, Gindville M, Brodsky M . Silent cerebral infarcts and cerebral aneurysms are prevalent in adults with sickle cell anemia. Blood. 2016; 127(16):2038-40. DOI: 10.1182/blood-2016-01-694562. View

Park S, Kim M, Brown K, DAgati V, Lee H . Paneth cell-derived interleukin-17A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury. Hepatology. 2011; 53(5):1662-75. PMC: 3082595. DOI: 10.1002/hep.24253. View

Dimmeler S, Zeiher A . Nitric oxide-an endothelial cell survival factor. Cell Death Differ. 1999; 6(10):964-8. DOI: 10.1038/sj.cdd.4400581. View

Lanaro C, Franco-Penteado C, Albuqueque D, Saad S, Conran N, Costa F . Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol. 2008; 85(2):235-42. DOI: 10.1189/jlb.0708445. View

Banda M, Lefer D, Granger D . Postischemic endothelium-dependent vascular reactivity is preserved in adhesion molecule-deficient mice. Am J Physiol. 1998; 273(6):H2721-5. DOI: 10.1152/ajpheart.1997.273.6.H2721. View

10.

Barabino G, Platt M, Kaul D . Sickle cell biomechanics. Annu Rev Biomed Eng. 2010; 12:345-67. DOI: 10.1146/annurev-bioeng-070909-105339. View

11.

Kato G, Piel F, Reid C, Gaston M, Ohene-Frempong K, Krishnamurti L . Sickle cell disease. Nat Rev Dis Primers. 2018; 4:18010. DOI: 10.1038/nrdp.2018.10. View

12.

Rothman S, Fulling K, Nelson J . Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol. 1986; 20(6):684-90. DOI: 10.1002/ana.410200606. View

13.

Sultana C, Shen Y, Rattan V, JOHNSON C, Kalra V . Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. Blood. 1998; 92(10):3924-35. View

14.

Hemmens B, Mayer B . Enzymology of nitric oxide synthases. Methods Mol Biol. 2000; 100:1-32. DOI: 10.1385/1-59259-749-1:1. View

15.

Eltzschig H, Eckle T . Ischemia and reperfusion--from mechanism to translation. Nat Med. 2011; 17(11):1391-401. PMC: 3886192. DOI: 10.1038/nm.2507. View

16.

Hogan M, Cerami A, Bucala R . Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest. 1992; 90(3):1110-5. PMC: 329972. DOI: 10.1172/JCI115928. View

17.

Kaestner L, Minetti G . The potential of erythrocytes as cellular aging models. Cell Death Differ. 2017; 24(9):1475-1477. PMC: 5563981. DOI: 10.1038/cdd.2017.100. View

18.

Telen M . Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. 2016; 127(7):810-9. PMC: 4760087. DOI: 10.1182/blood-2015-09-618553. View

19.

Kato G . Anemia, age, desaturation, and impaired neurocognition in sickle cell anemia. Pediatr Blood Cancer. 2012; 59(5):773-4. PMC: 3442134. DOI: 10.1002/pbc.24276. View

20.

Herrick J . Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910. Yale J Biol Med. 2001; 74(3):179-84. PMC: 2588723. View